GlassScriptPhysician profile
Shaun D Conlon
NPI 1760667034
$10,990.54
in general payments reported to CMS, 2019-2025
26 companies · $601 in 2025
The $601 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,468 · 2020: $470 · 2021: $614 · 2022: $742 · 2023: $687 · 2024: $4,407 · 2025: $601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,400 · Food and Beverage: $2,306 · Travel and Lodging: $976 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,400.00 |
| Food and Beverage | $2,305.93 |
| Travel and Lodging | $976.31 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $4,498.75 | 2019-2025 | Velphoro, Velphoro |
| Ultragenyx Pharmaceutical INC. | $2,808.58 | 2019 | |
| Vifor Pharma, INC. | $938.74 | 2019-2025 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $694.57 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $265.88 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $222.59 | 2019-2025 | Jynarque, Voyxact |
| Travere Therapeutics, INC. | $219.87 | 2019-2025 | Thiola |
| Amgen INC. | $173.56 | 2019-2025 | Krystexxa |
| Akebia Therapeutics INC | $173.08 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $162.99 | 2024-2025 | |
| Opko Pharmaceuticals, LLC | $109.17 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $106.60 | 2022 | |
| Aurinia Pharma U.S., INC. | $99.96 | 2021-2023 | Lupkynis |
| Lilly USA, LLC | $91.20 | 2023-2024 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.59 | 2024-2025 | Jardiance |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $70.52 | 2019-2021 | |
| Calliditas Therapeutics US INC. | $68.52 | 2023-2025 | Tarpeyo |
| Ardelyx, INC. | $41.97 | 2023-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $36.52 | 2023-2024 | Benlysta |
| Nxstage Medical, INC. | $24.36 | 2022 | |
| Scpharmaceuticals INC. | $22.78 | 2025 | |
| Apellis Pharmaceuticals, INC. | $21.38 | 2025 | Empaveli |
| Alnylam Pharmaceuticals INC. | $18.02 | 2022 | |
| Genzyme Corporation | $17.33 | 2019 | |
| Amag Pharmaceuticals, INC. | $17.31 | 2019 | |
| Horizon Therapeutics Plc | $15.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaun Conlon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.